1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)

H Léna ,H Curcio,C Rieux,L De Gunten,C Deldycke,A-C Madroszyk Flandin,L Pabst,A-C Métivier,R Gille,J.B Auliac,Olivier Bylicki ,Hamadi Almotlak ,Éric Pichon ,Fabrice Barlési ,Boris Duchemann ,Sébastien Couraud ,Nicolas Girard ,Julien Mazières ,Jacques Cadranel ,Xavier Quantin

doi:10.1016/j.annonc.2023.09.2436

1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)

H Léna , H Curcio + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.2436

Copy DOI

#Temporary Authorization Of Use #Metastatic Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)

Full Text